Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622688 | 0.88 | POLB (0.46) | CREBBPBRD4MAPTCYP1A2CYP2C19 | |
| SCHEMBL1608768 | 0.84 | CREBBP (0.44) | CREBBPBRD4MAPTCYP1A2CYP2C19 | |
| SCHEMBL1609240 | 0.82 | CNR2 (0.44) | CREBBPBRD4MAPTCYP1A2CYP2C19 | |
| SCHEMBL1609124 | 0.81 | PTGER4 (0.48) | CREBBPBRD4MAPTCYP1A2CYP2C19 | |
| SCHEMBL14116543 | 0.79 | HTT (0.44) | CREBBPBRD4MAPTCYP1A2CYP2C19 | |
| SCHEMBL1609171 | 0.78 | HTT (0.58) | MAPTCYP1A2CYP2C19NPSR1 | |
| SCHEMBL5881733 | 0.71 | PTGER4 (0.56) | CYP1A2CYP2C19NPSR1MAPK14PIK3C3 | |
| SCHEMBL18406296 | 0.71 | HTT (0.48) | MAPTCYP1A2CYP2C19MAPK14PIK3C3 | |
| SCHEMBL10048290 | 0.70 | MAPK14 (0.39) | CYP1A2CYP2C19NPSR1MAPK14PIK3C3 | |
| SCHEMBL3995887 | 0.70 | CREBBP (0.43) | CREBBPMAPTCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615642-B2 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | OPRM1, OPRL1, OPRK1 | CREBBP 1782/4885BRD4 1851/4885MAPT 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.